
Sign up to save your podcasts
Or
What happens when you connect Trump’s new drug-buying website, TrumpRx, with the ongoing conversation about cannabis rescheduling? The answer could reshape both healthcare and the cannabis industry.TrumpRx is designed as a government-backed platform to let Americans access prescription drugs at lower prices, with Pfizer as its launch partner. On its own, that’s a big deal. But when you add the potential for cannabis rescheduling — moving it from Schedule I to Schedule III — the dots begin to connect in new and important ways.If cannabis is recognized as a federally legitimate medicine, it could eventually find a place on TrumpRx or similar programs. That opens the door for Big Pharma to step in — companies like Pfizer, Merck, or Johnson & Johnson — and bring their scale, research, and lobbying power into cannabinoids. For patients, this could mean easier access and lower costs. For the cannabis sector, it could mean legitimacy and new investor attention.But there are cautions. Big Pharma’s entry could bring pricing pressure, increased competition, and the risk that cannabis access shifts away from dispensaries and toward a system controlled by traditional pharmaceutical channels. Smaller cannabis operators need to prepare now.TDR Cannabis in 5, presented by Dutchie, walks through how TrumpRx, cannabis rescheduling, and Big Pharma could collide to reshape healthcare, industry strategy, and investor outlook.The cannabis industry stands at a crossroads. Adaptation will decide who thrives and who gets left behind.#TrumpRx #CannabisRescheduling #BigPharma #CannabisStocks #ScheduleIII #DonaldTrump #Pfizer #MarijuanaReclassification #CannabisNews #TrumpMarijuana #USNews #LegalizationOfMarijuanaWant to see last week's recap? • Weekly Recap: Supreme Court Showdown Over ... Want to see more Cannabis Reform videos? • Senator Ties Cannabis Rescheduling to Bank... • Trump Endorses Cannabis in Truth Social Vi... • Congress Faces Backlash Over Hemp THC Ban ... • Is Biased Polling Shaping Cannabis Reform?... Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook: / thedalesreport Twitter: / thedalesreport Instagram: / dalesreport LinkedIn: / the-dales-report Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...
5
77 ratings
What happens when you connect Trump’s new drug-buying website, TrumpRx, with the ongoing conversation about cannabis rescheduling? The answer could reshape both healthcare and the cannabis industry.TrumpRx is designed as a government-backed platform to let Americans access prescription drugs at lower prices, with Pfizer as its launch partner. On its own, that’s a big deal. But when you add the potential for cannabis rescheduling — moving it from Schedule I to Schedule III — the dots begin to connect in new and important ways.If cannabis is recognized as a federally legitimate medicine, it could eventually find a place on TrumpRx or similar programs. That opens the door for Big Pharma to step in — companies like Pfizer, Merck, or Johnson & Johnson — and bring their scale, research, and lobbying power into cannabinoids. For patients, this could mean easier access and lower costs. For the cannabis sector, it could mean legitimacy and new investor attention.But there are cautions. Big Pharma’s entry could bring pricing pressure, increased competition, and the risk that cannabis access shifts away from dispensaries and toward a system controlled by traditional pharmaceutical channels. Smaller cannabis operators need to prepare now.TDR Cannabis in 5, presented by Dutchie, walks through how TrumpRx, cannabis rescheduling, and Big Pharma could collide to reshape healthcare, industry strategy, and investor outlook.The cannabis industry stands at a crossroads. Adaptation will decide who thrives and who gets left behind.#TrumpRx #CannabisRescheduling #BigPharma #CannabisStocks #ScheduleIII #DonaldTrump #Pfizer #MarijuanaReclassification #CannabisNews #TrumpMarijuana #USNews #LegalizationOfMarijuanaWant to see last week's recap? • Weekly Recap: Supreme Court Showdown Over ... Want to see more Cannabis Reform videos? • Senator Ties Cannabis Rescheduling to Bank... • Trump Endorses Cannabis in Truth Social Vi... • Congress Faces Backlash Over Hemp THC Ban ... • Is Biased Polling Shaping Cannabis Reform?... Want to be updated on Cannabis, Small Cap, AI, and Crypto? Subscribe to our Daily Baked in Newsletter!https://newsletter.thedalesreport.com...Find us as well on Facebook, Twitter, Instagram, LinkedIn and on the Web:Facebook: / thedalesreport Twitter: / thedalesreport Instagram: / dalesreport LinkedIn: / the-dales-report Apple Podcasts: https://tinyurl.com/TDRTradetoBlackon...Spotify: https://tinyurl.com/TDRTradeToBlackon...Website: https://thedalesreport.com/For copyright matters, please get in touch with us at:[email protected] Disclaimer (Financial Interests)The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company, organization, or employer. The content is provided for informational and entertainment purposes only and should not be taken as financial, investment, or legal advice.The hosts and/or guests may hold positions in the companies, stocks, or financial instruments discussed during the show. These holdings should not be considered as endorsements or recommendations to buy or sell any securities. Listeners are encouraged to do their own research or consult with a qualified financial advisor before making any investment decisions.By listening to this podcast, you agree that the hosts, guests, and producers are not liable for any decisions you make based on the information discussed.Full Disclosures: https://thedalesreport.com/website-te...
39 Listeners
3,791 Listeners
94 Listeners
1,839 Listeners
204 Listeners
67 Listeners
5,447 Listeners
409 Listeners
107 Listeners
29,342 Listeners
8,776 Listeners
154 Listeners
7 Listeners
14 Listeners
1,295 Listeners